Literature DB >> 19892545

Pharmacological significance of glycosylation in therapeutic proteins.

Huijuan Li1, Marc d'Anjou.   

Abstract

Glycoproteins represent the major share of marketed and clinical development phase therapeutic proteins. A thorough understanding of the nature and function of the carbohydrate moiety and its impact on pharmacology properties is essential in discovering and developing safe and efficacious glycoprotein biopharmaceuticals. This review summarizes the processes of N-linked and O-linked glycosylation and both established and emerging platforms for expression of recombinant glycoproteins. Recent or illustrative examples of N-linked and/or O-linked glycosylation impacting drug pharmacology properties (including activity, pharmacokinetics, clearance, and immunogenicity) of marketed and developing therapeutic proteins are presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892545     DOI: 10.1016/j.copbio.2009.10.009

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  65 in total

1.  A Markov chain model for N-linked protein glycosylation--towards a low-parameter tool for model-driven glycoengineering.

Authors:  Philipp N Spahn; Anders H Hansen; Henning G Hansen; Johnny Arnsdorf; Helene F Kildegaard; Nathan E Lewis
Journal:  Metab Eng       Date:  2015-10-29       Impact factor: 9.783

2.  Rapid release of N-linked glycans from glycoproteins by pressure-cycling technology.

Authors:  Zoltan Szabo; András Guttman; Barry L Karger
Journal:  Anal Chem       Date:  2010-03-15       Impact factor: 6.986

3.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

4.  Enterococcus faecalis α1-2-mannosidase (EfMan-I): an efficient catalyst for glycoprotein N-glycan modification.

Authors:  Yanhong Li; Riyao Li; Hai Yu; Xue Sheng; Jing Wang; Andrew J Fisher; Xi Chen
Journal:  FEBS Lett       Date:  2019-10-08       Impact factor: 4.124

5.  Biosimilars 2.0: guiding principles for a global "patients first" standard.

Authors:  Joseph Miletich; Geoffrey Eich; Gustavo Grampp; Barbara Mounho
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

6.  Effects of clonal variation on growth, metabolism, and productivity in response to trophic factor stimulation: a study of Chinese hamster ovary cells producing a recombinant monoclonal antibody.

Authors:  Hussain Dahodwala; Mark Nowey; Tatyana Mitina; Susan T Sharfstein
Journal:  Cytotechnology       Date:  2011-08-06       Impact factor: 2.058

7.  Comparability analysis of protein therapeutics by bottom-up LC-MS with stable isotope-tagged reference standards.

Authors:  Anton V Manuilov; Czeslaw H Radziejewski; David H Lee
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

Review 8.  Recent Advances in the Analysis of Complex Glycoproteins.

Authors:  Stefan Gaunitz; Gabe Nagy; Nicola L B Pohl; Milos V Novotny
Journal:  Anal Chem       Date:  2016-11-23       Impact factor: 6.986

Review 9.  Cell-Free Synthetic Biology: Engineering Beyond the Cell.

Authors:  Jessica G Perez; Jessica C Stark; Michael C Jewett
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

Review 10.  Bioinformatics and molecular modeling in glycobiology.

Authors:  Martin Frank; Siegfried Schloissnig
Journal:  Cell Mol Life Sci       Date:  2010-04-04       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.